Companies

Alembic Pharma gets final approval from USFDA for OCD treatment drug

PTI New Delhi | Updated on August 05, 2021

The approved product is therapeutically equivalent to the reference-listed drug product Anafranil Capsules of SpecGX LLC

Drug firm Alembic Pharmaceuticals on Thursday said it has received final approval from the US health regulator for Clomipramine Hydrochloride capsules, used for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Clomipramine Hydrochloride Capsules USP in the strengths 25 mg, 50 mg, and 75 mg, Alembic Pharmaceuticals said in a regulatory filing.

Also read: Alembic Pharma bags USFDA final nod for orthostatic hypotension tablets

The approved product is therapeutically equivalent to the reference-listed drug product Anafranil Capsules of SpecGX LLC.

Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with OCD.

Quoting IQVIA data, Clomipramine Hydrochloride Capsules USP25 mg, 50 mg, and 75 mg have an estimated market size of USD 32 million for twelve months ending June 2021.

Alembic has a cumulative total of 149 abbreviated new drug application (ANDA) approvals, which includes 131 final approvals and 18 tentative approvals, from USFDA.

Published on August 05, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like